![Eric Easom](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric Easom
Verkställande Direktör på
AN2 THERAPEUTICS, INC.
Förmögenhet: 7 M $ per 2026-06-30
Profil
Eric Easom is the founder of AN2 Therapeutics, Inc., founded in 2017, where the title held is Chairman, President & Chief Executive Officer since 2024.
Current jobs include Director at Resilient Biotics, Inc. since 2019 and Director at Chagas Disease Foundation since 2018.
Former jobs include Senior Director-Business Development & Marketing at InteKrin Therapeutics, Inc. from 2007 to 2009, Director at Infectious Disease Research Institute from 2013 to 2014, and Vice President-Neglected Diseases at Anacor Pharmaceuticals LLC from 2009 to 2017.
Education includes undergraduate studies at the University of Louisville and an MBA from Kelley School of Business.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC. 3,77 % | 2026-03-31 | 1 357 825 ( 3,77 % ) | 7 M $ | 2026-06-30 |
Aktiva positioner av Eric Easom
| Företag | Position | Start |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Verkställande Direktör | 2019-11-01 |
Chagas Disease Foundation | Direktör/Styrelseledamot | 2018-06-01 |
Resilient Biotics, Inc.
 Resilient Biotics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops microbiome-based therapeutics | Direktör/Styrelseledamot | 2019-02-01 |
Tidigare kända positioner av Eric Easom
| Företag | Position | Slut |
|---|---|---|
| ANACOR PHARMACEUTICALS INC | Företagsledare/Principal | 2017-06-01 |
Infectious Disease Research Institute
 Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases | Ordförande | 2013-01-01 |
InteKrin Therapeutics, Inc.
 InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for metabolic and immune disorders | Försäljning & Marknadsföring | 2009-01-01 |
Eric Easoms utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
28
Första gradens relationer
8
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 8 |
|---|---|
InteKrin Therapeutics, Inc.
InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for metabolic and immune disorders | Health Technology |
University of Louisville
 University of Louisville Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Operates as a bio pharmaceutical company | Health Technology |
Infectious Disease Research Institute
Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases | Commercial Services |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Resilient Biotics, Inc.
Resilient Biotics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops microbiome-based therapeutics | Commercial Services |
AN2 Therapeutics, Inc.
 AN2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics | Health Technology |
Chagas Disease Foundation |
